137 related articles for article (PubMed ID: 11800042)
1. A double-blind placebo-controlled clinical trial of recombinant human brain-derived neurotrophic factor (rhBDNF) in diabetic polyneuropathy.
Wellmer A; Misra VP; Sharief MK; Kopelman PG; Anand P
J Peripher Nerv Syst; 2001 Dec; 6(4):204-10. PubMed ID: 11800042
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group.
Apfel SC; Schwartz S; Adornato BT; Freeman R; Biton V; Rendell M; Vinik A; Giuliani M; Stevens JC; Barbano R; Dyck PJ
JAMA; 2000 Nov; 284(17):2215-21. PubMed ID: 11056593
[TBL] [Abstract][Full Text] [Related]
3. Quantitative sensory and autonomic testing in male diabetic patients with erectile dysfunction.
Wellmer A; Sharief MK; Knowles CH; Misra VP; Kopelman P; Ralph D; Anand P
BJU Int; 1999 Jan; 83(1):66-70. PubMed ID: 10233454
[TBL] [Abstract][Full Text] [Related]
4. Limits of the sympathetic skin response in patients with diabetic polyneuropathy.
Bril V; Nyunt M; Ngo M
Muscle Nerve; 2000 Sep; 23(9):1427-30. PubMed ID: 10951447
[TBL] [Abstract][Full Text] [Related]
5. Neuropathy is a major contributing factor to diabetic erectile dysfunction.
Hecht MJ; Neundörfer B; Kiesewetter F; Hilz MJ
Neurol Res; 2001 Sep; 23(6):651-4. PubMed ID: 11547937
[TBL] [Abstract][Full Text] [Related]
6. The value of testing for unmyelinated fibre, sensory neuropathy in diabetic impotence.
Fowler CJ; Ali Z; Kirby RS; Pryor JP
Br J Urol; 1988 Jan; 61(1):63-7. PubMed ID: 3342303
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy.
Polydefkis M; Arezzo J; Nash M; Bril V; Shaibani A; Gordon RJ; Bradshaw KL; Junor RW;
J Peripher Nerv Syst; 2015 Dec; 20(4):363-71. PubMed ID: 26313450
[TBL] [Abstract][Full Text] [Related]
8. The effect of gamma-linolenic acid on human diabetic peripheral neuropathy: a double-blind placebo-controlled trial.
Jamal GA; Carmichael H
Diabet Med; 1990 May; 7(4):319-23. PubMed ID: 2159860
[TBL] [Abstract][Full Text] [Related]
9. Treatment of diabetic polyneuropathy with the neurotrophic peptide ORG 2766.
Valk GD; Kappelle AC; Tjon-A-Tsien AM; Bravenboer B; Bakker K; Michels RP; Groenhout CM; Bertelsmann FW
J Neurol; 1996 Mar; 243(3):257-63. PubMed ID: 8936356
[TBL] [Abstract][Full Text] [Related]
10. Topical Citrullus colocynthis (bitter apple) extract oil in painful diabetic neuropathy: A double-blind randomized placebo-controlled clinical trial.
Heydari M; Homayouni K; Hashempur MH; Shams M
J Diabetes; 2016 Mar; 8(2):246-52. PubMed ID: 25800045
[TBL] [Abstract][Full Text] [Related]
11. The effect of ubiquinone in diabetic polyneuropathy: a randomized double-blind placebo-controlled study.
Hernández-Ojeda J; Cardona-Muñoz EG; Román-Pintos LM; Troyo-Sanromán R; Ortiz-Lazareno PC; Cárdenas-Meza MA; Pascoe-González S; Miranda-Díaz AG
J Diabetes Complications; 2012; 26(4):352-8. PubMed ID: 22595020
[TBL] [Abstract][Full Text] [Related]
12. A Clinical Trial of Nitrosense patch for the treatment of patients with painful diabetic neuropathy.
Agrawal RP; Jain S; Goyal S; Singhal S; Lindgren L; Sthengel E
J Assoc Physicians India; 2014 May; 62(5):385-90. PubMed ID: 25438482
[TBL] [Abstract][Full Text] [Related]
13. Comparison of vibration perception thresholds obtained with the Neurothesiometer and the CASE IV and relationship to nerve conduction studies.
Bril V; Perkins BA
Diabet Med; 2002 Aug; 19(8):661-6. PubMed ID: 12147147
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous thermal thresholds in normal subjects and diabetic patients without symptoms of peripheral neuropathy.
Lin HJ; Chiu HC; Tchen PH; Fu CC
J Formos Med Assoc; 1990 Oct; 89(10):857-62. PubMed ID: 1981772
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group.
Apfel SC; Kessler JA; Adornato BT; Litchy WJ; Sanders C; Rask CA
Neurology; 1998 Sep; 51(3):695-702. PubMed ID: 9748012
[TBL] [Abstract][Full Text] [Related]
16. Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24-week controlled trial.
Fagius J; Brattberg A; Jameson S; Berne C
Diabetologia; 1985 Jun; 28(6):323-9. PubMed ID: 3930330
[TBL] [Abstract][Full Text] [Related]
17. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial.
Ametov AS; Barinov A; Dyck PJ; Hermann R; Kozlova N; Litchy WJ; Low PA; Nehrdich D; Novosadova M; O'Brien PC; Reljanovic M; Samigullin R; Schuette K; Strokov I; Tritschler HJ; Wessel K; Yakhno N; Ziegler D;
Diabetes Care; 2003 Mar; 26(3):770-6. PubMed ID: 12610036
[TBL] [Abstract][Full Text] [Related]
18. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy.
Ekberg K; Brismar T; Johansson BL; Lindström P; Juntti-Berggren L; Norrby A; Berne C; Arnqvist HJ; Bolinder J; Wahren J
Diabetes Care; 2007 Jan; 30(1):71-6. PubMed ID: 17192336
[TBL] [Abstract][Full Text] [Related]
19. Is ACE inhibition with lisinopril helpful in diabetic neuropathy?
Reja A; Tesfaye S; Harris ND; Ward JD
Diabet Med; 1995 Apr; 12(4):307-9. PubMed ID: 7600744
[TBL] [Abstract][Full Text] [Related]
20. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients.
Ziegler D; Movsesyan L; Mankovsky B; Gurieva I; Abylaiuly Z; Strokov I
Diabetes Care; 2009 Aug; 32(8):1479-84. PubMed ID: 19470838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
